Recent developments in liver pathology

Human Pathology

Volumn 40, Issue 4, 2009, Pages 445-455

  Lefkowitch, Jay H ^a  

^a Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

Author keywords

Fatty liver; Glypican 3; Iron; Liver; Liver biopsy; Liver tumors; Mallory Denk body

Indexed keywords

AMIODARONE; BORTEZOMIB; GLYPICAN 3;

ARTICLE; AUTOIMMUNE HEPATITIS; FATTY LIVER; GENOMICS; HEPATITIS C; HEPATITIS E; HEPATOBILIARY DISEASE; HERPES VIRUS INFECTION; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOHISTOCHEMISTRY; IRON OVERLOAD; LIVER CELL CARCINOMA; LIVER TOXICITY; LIVER TRANSPLANTATION; LIVER TUMOR; MALLORY BODY; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOGENESIS;

HUMANS; LIVER DISEASES;

EID: 61949273572     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2008.12.014     Document Type: Article

References (108)

1. Puius Y.A., Dove L.M., Brust D.G., et al. Three cases of autoimmune hepatitis in HIV-infected patients. J Clin Gastroenterol 42 (2008) 424-429
2. Drebber U., Kasper H.-U., Ratering J., et al. Hepatic granulomas: histological and molecular pathological approach to differential diagnosis-a study of 442 cases. Liver Int 28 (2008) 828-834
3. Strautnieks S.S., Byrne J.A., Pawlikowska L., et al. Severe bile salt export pump deficiency: 82 different ACB11 mutations in 109 families. Gastroenterology 134 (2008) 1203-1214
4. Ziol M., Barbu V., Rosmorduc O., et al. ABCB4 heterozygous gene mutations associated with fibrosing cholestatic liver disease in adults. Gastroenterology 135 (2008) 131-141
5. Brunt E.M. Do you see what I see? The role of quality histopathology in scientific study. Hepatology 47 (2008) 771-774
6. Phillips M.J., Blendis L.M., Paucell S., et al. Syncytial giant-cell hepatitis. Sporadic hepatitis with distinctive pathologic features, a severe clinical course, and paramyxoviral features. N Engl J Med 324 (1991) 455-460
7. Devaney K., Goodman Z.D., and Ishak K.G. Postinfantile giant-cell transformation in hepatitis. Hepatology 16 (1992) 327-333
8. Potenza L., Luppi M., Barozzi P., et al. HHV-6A in syncytial giant-cell hepatitis. N Engl J Med 359 (2008) 593-602
9. Micchelli S.T.L., Thomas D., Boitnott J.K., et al. Hepatic giant cells in hepatitis C virus (HCV) mono-infection and HCV/HIV co-infection. J Clin Pathol 61 (2008) 1058-1061
10. Moreno A., Moreno A., Pérez-Elias M.J., et al. Syncytial giant cell hepatitis in human immunodeficiency virus-infected patients with chronic hepatitis C: 2 cases and review of the literature. Hum Pathol 37 (2006) 1344-1349
11. Pessõa M.G., Alves V.A.F., Wakamatsu A., et al. Post-transplant recurrent hepatitis C: immunohistochemical detection of hepatitis C virus core antigen and possible pathogenic implications. Liver Int 28 (2008) 807-813
12. Haagsma E.B., van den Berg A.P., Porte R.J., et al. Chronic hepatitis E virus infection in liver transplant recipients. Liver Transpl 14 (2008) 547-553
13. Kamar N., Selves J., Mansuy J.-M., et al. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med 358 (2008) 811-817
14. Kamar N., Mansuy J.-M., Cointault O., et al. Hepatitis E virus-related cirrhosis in kidney- and kidney-pancreas-transplant recipients. Am J Transplant 8 (2008) 1744-1748
15. Gerolami R., Moal V., and Colson P. Chronic hepatitis E with cirrhosis in a kidney-transplant recipient. N Engl J Med 358 (2008) 89-860
16. Purcell R.H., and Emerson S.U. Hepatitis E: an emerging awareness of an old disease. J Hepatol 48 (2008) 494-503
17. Navaneethan U., Al Mohajer M., and Shata M.T. Hepatitis E and pregnancy: understanding the pathogenesis. Liver Int 28 (2008) 1190-1199
18. Aggarwal R. Hepatitis E: does it cause chronic hepatitis?. Hepatology 48 (2008) 1328-1330
19. Malcolm P., Dalton H., Hussaini H.S., et al. The histology of acute autochthonous hepatitis E virus infection. Histopathology 51 (2007) 190-194
20. Goodman Z.D., Makhlouf H.R., Liu L., et al. Pathology of chronic hepatitis C in children: liver biopsy findings in the Peds-C trial. Hepatology 47 (2008) 836-843
21. Sheikh M.Y., Choi J., Qadri I., et al. Hepatitis C virus infection: molecular pathways to metabolic syndrome. Hepatology 47 (2008) 2127-2133
22. Czaja A.J., and Carpenter H.A. Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology 105 (1993) 1824-1832
23. Alvarez F., Berg P.A., Biandin F.B., et al. International Autoimmune Hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 31 (1999) 929-938 [Ref Type: Generic]
24. Hennes E.M., Zeniya M., Czaja A.J., et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 48 (2008) 169-176
25. Zatloukal K., French S.W., Stumptner C., et al. From Mallory to Mallory-Denk bodies: what, how and why?. Exp Cell Res 313 (2007) 2033-2049
26. Parker F. Frank Burr Mallory. Am J Pathol 17 (1941) 785-786
27. Mallory F.B. Cirrhosis of the liver. Five different types of lesions from which it may arise. Bull Johns Hopkins Hosp 22 (1911) 69-74
28. Strnad P., Zatloukal K., Stumptner C., et al. Mallory-Denk bodies: lessons from keratin-containing hepatic inclusion bodies. Biochim Biophys Acta 1782 (2008) 764-774
29. Strnad P., Stumptner C., Zatloukal K., et al. Intermediate filament cytoskeleton of the liver in health and disease. Histochemistry and Cell Biology 129 (2008) 735-749
30. Yeh M.M., and Brunt E.M. Pathology of nonalcoholic fatty liver disease. Am J Clin Pathol 128 (2007) 837-847
31. Hanada S., Strnad P., Brunt E.M., et al. The genetic background modulates susceptibility to mouse liver Mallory-Denk body formation and liver injury. Hepatology 48 (2008) 943-952
32. Strnad P., Tao G.-Z.S.P., et al. "Toxic memory" via chaperone modification is a potential mechanism for rapid Mallory-Denk body reinduction. Hepatology 48 (2008) 931-942
33. Harada M., Hanada S., Toivola D.M., et al. Autophagy activation by rapamycin eliminates mouse Mallory-Denk bodies and blocks their proteasome inhibitor-mediated formation. Hepatology 47 (2008) 2026-2035
34. Charlton M. Cirrhosis and liver failure in nonalcoholic fatty liver disease: molehill or mountain?. Hepatology 47 (2008) 1431-1433
35. Goessling W., Massaro J.M., Vasan R.S., et al. Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease. Gastroenterology 135 (2008) 1935-1944
36. Matteoni C.A., Younossi Z.M., Gramlich T., et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116 (1999) 1413-1419
37. Abrams G.A., Kunde S.S., Lazenby A.J., et al. Portal fibrosis and hepatic steatosis in morbidly obese subjects: a spectrum of nonalcoholic fatty liver disease. Hepatology 40 (2004) 475-483
38. Adler M., and Schaffner F. Fatty liver hepatitis and cirrhosis in obese patients. Am J Med 67 (1979) 811-816
39. Schwimmer J.B., Behling C., Newbury R., et al. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology 42 (2005) 641-649
40. Patton H.M., Lavine J.E., Van Natta M.L., et al. Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis. Gastroenterology 135 (2008) 1961-1971
41. Ronchetti A., Prati D., Pezzotta M.G., et al. Severe steatohepatitis in a patient with a rare neutral lipid storage disorder due to ABDH5 mutation. J Hepatol 49 (2008) 474-477
42. Ekstedt M., Franzen L.E., Mathiesen U.L., et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44 (2006) 865-873
43. Sanyal A.J., Banas C., Sargeant C., et al. Similarities and differences in outcomes of cirrhosis due to non-alcoholic steatohepatitis and hepatitis C. Hepatology 43 (2006) 682-689
44. de Alwis N.M.W., and Day C.P. Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol 48 (2008) S104-S112
45. Chalasani N., WIlson L., Kleiner D.E., et al. Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease. J Hepatol 48 (2008) 829-834
46. Gramlich T., Kleiner D.E., McCullough A.J., et al. Pathologic features associated with fibrosis in nonalcoholic fatty liver disease. Hum Pathol 35 (2004) 196-199
47. Lackner C., Gogg-Kamerer M., Zatloukal K., et al. Ballooned hepatocytes in steatohepatitis: the value of keratin immunohistochemistry for diagnosis. J Hepatol 48 (2008) 821-828
48. Robin M.-A., Descatoire V., Pessayre D., et al. Steatohepatitis-inducing drugs trigger cytokeratin cross-links in hepatocytes. Possible contribution to Mallory-Denk body formation. Toxicology In Vitro 22 (2008) 1511-1519
49. Feder J.N., Gnirke A., Thomas W., et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nature Genet 13 (1996) 399-408
50. Deugnier Y., Brissot P., and Loréal O. Iron and the liver: update 2008. J Hepatol 48 (2008) S113-S123
51. Brissot P., Troadec M.-B., Bardou-Jacquet E., et al. Current approach to hemochromatosis. Blood Rev 22 (2008) 195-210
52. Graham R.M., Chua A.C.G., Herbison C.E., et al. Liver iron transport. World J Gastroenterol 13 (2007) 4725-4736
53. Pietrangelo A. Hemochromatosis: an endocrine liver disease. Hepatology 46 (2007) 1291-1301
54. Girelli D., De Deomenico I., Bozzini C., et al. Clinical, pathological, and molecular correlates in ferroportin disease: a study of two novel mutations. J Hepatol 49 (2008) 664-671
55. Barisani D., Pelucchi S., Mariani R., et al. Hepcidin and iron-related gene expression in subjects with dysmetabolic hepatic iron overload. J Hepatol 49 (2008) 123-133
56. Turlin B., Mendler M.H., Moirand R., et al. Histologic features of the liver in insulin resistance-associated iron overload. A study of 139 patients. Am J Clin Pathol 116 (2001) 263-270
57. Aigner E., Theurl I., Haufe H., et al. Copper availability contributes to iron perturbations in human nonalcoholic fatty liver disease. Gastroenterology 135 (2008) 680-688
58. Bergmann O.M., Mathahs M.M., Broadhurst K.A., et al. Altered expression of iron regulatory genes in cirrhotic human livers: clues to the cause of hemosiderosis?. Lab Invest 88 (2008) 1349-1357
59. Kakar S., Gown A.M., Goodman Z.D., et al. Best practices in diagnostic immunohistochemistry. Hepatocellular carcinoma versus metastatic neoplasms. Arch Pathol Lab Med 133 (2007) 1648-1654
60. Di Tommaso L., Franchi G., Park Y.N., et al. Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology 45 (2007) 725-734
61. Ligato S., Mandich D., and Cartun R.W. Utility of glypican-3 in differentiating hepatocellular carcinoma from other primary and metastatic lesions in FNA of the liver: an immunocytochemical study. Modern Pathol 21 (2008) 626-631
62. Coston W.M.P., Loera S., Lau S.K., et al. Distinction of hepatocellular carcinoma from benign hepatic mimickers using glypican-3 and CD34 immunohistochemistry. Am J Surg Pathol 32 (2008) 433-444
63. Butler S.L., Dong H., Cardona D., et al. The antigen for Hep Par 1 antibody is the urea cycle enzyme carbamoyl phosphate synthetase 1. Lab Invest 88 (2008) 78-88
64. Shafizadeh N., Ferrell L.D., and Kakar S. Utility and limitations of glypican-3 expression for the diagnosis of hepatocellular carcinoma at both ends of the differentiation spectrum. Modern Pathol 21 (2008) 1011-1018
65. Abdul-AL H.M., Makhlouf H.R., Wang G., et al. Glypican-3 expression in benign liver tissue with active hepatitis C: implications for the diagnosis of hepatocellular carcinoma. Hum Pathol 39 (2008) 209-212
66. Baumhoer D., Tornillo L., Stadlmann S., et al. Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues. A tissue microarray analysis of 4,387 tissue samples. Am J Clin Pathol 129 (2008) 899-906
67. Zynger D.L., Everton M.J., Dimov N.D., et al. Expression of glypican 3 in ovarian and extragonadal germ cell tumors. Am J Clin Pathol 130 (2008) 224-230
68. Aviel-Ronen S., Lau S.K., Pintilie M., et al. Glypican-3 is overexpressed in lung squamous cell carcinoma, but not in adenocarcinoma. Modern Pathol 21 (2008) 817-825
69. Skawran B., Steinemann D., Weigmann A., et al. Gene expression profiling in hepatocellular carcinoma: upregulation of genes in amplified chromosome regions. Modern Pathol 21 (2008) 505-516
70. Vivekanandan P., and Torbenson M. Epigenetic instability is rare in fibrolamellar carcinomas but common in viral-associated hepatocellular carcinomas. Modern Pathol 21 (2008) 670-675
71. Wong C.-M., and Ng O.L. Molecular pathogenesis of hepatocellular carcinoma. Liver Int 28 (2008) 160-174
72. Hoshida Y., Villanueva A., Kobayashi M., et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 359 (2008) 1995-2004
73. Schlaeger C., Longerich T., Schiller C., et al. Etiology-dependent molecular mechanisms in human hepatocarcinogenesis. Hepatology 47 (2008) 511-520
74. Guzman G., Brunt E.M., Petrovic L.M., et al. Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis?. Arch Pathol Lab Med 132 (2008) 1761-1766
75. Asselah T., Bièche I., Laurendeau I., et al. Significant gene expression differences in histologically "normal" liver biopsies: implications for control tissue. Hepatology 48 (2008) 953-962
76. Blechacz B., and Gores G.J. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology 48 (2008) 308-321
77. Weismüller T.J., Wedemeyer J., Kubicka S., et al. The challenges in primary sclerosing cholangitis-aetiopathogenesis, autoimmunity, management and malignancy. J Hepatol 48 (2008) S38-S57
78. Björnsson E., Olsson R., Bergquist A., et al. The natural history of small-duct primary sclerosing cholangitis. Gastroenterology 134 (2008) 975-980
79. Nishino R., Honda M., Yamashita T., et al. Identification of novel candidate tumour marker genes for intrahepatic cholangiocarcinoma. J Hepatol 49 (2008) 207-216
80. Blechacz B., and Gores G.J. Tumor-specific marker genes for intrahepatic cholangiocarcinoma: utility and mechanistic insight. J Hepatol 49 (2008) 160-162
81. Komuta M., Spee B., Borght S.V., et al. Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin. Hepatology 47 (2008) 1544-1556
82. Fujii T., Zen Y., Harada K., et al. Participation of liver cancer stem/progenitor cells in tumorigenesis of scirrhous hepatocellular carcinoma-human and cell culture study. Hum Pathol 39 (2008) 1185-1196
83. Zhang F., Chen X.-P., Zhang W., et al. Combined hepatocellular cholangiocarcinoma originating from hepatic progenitor cells: immunohistochemical and double-fluorescence immunostaining evidence. Histopathology 52 (2008) 224-232
84. Roskams T. Different types of liver progenitor cells and their niches. J Hepatol 45 (2006) 1-4
85. Kuwahara R., Kofman A.V., Landis C.S., et al. The hepatic stem cell niche: identification by label-retaining cell assay. Hepatoloy 47 (2008) 1994-2002
86. Petersen B., and Shupe T. Location is everything: the liver stem cell niche. Hepatology 47 (2008) 1810-1812
87. Bioulac-Sage P., Blanc J.F., Rebouissou S., et al. Genotype phenotype classification of hepatocellular adenoma. World J Gastroenterol 13 (2007) 2649-2654
88. Bioulac-Sage P., Rebouissou S., Thomas C., et al. Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology 46 (2007) 740-748
89. Bioulac-Sage P., Balabaud C., Bedossa P., et al. Pathological diagnosis of liver cell adenoma and focal nodular hyperplasia: Bordeaux update. J Hepatol 46 (2007) 521-527
90. Rebouissou S., Amessou M., Couchy G., et al. Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature 457 (2009) 200-204
91. Micchelli S.T.L., Vivekanandan P., Boitnott J.K., et al. Malignant transformation of hepatic adenomas. Modern Pathol 21 (2008) 491-497
92. Iyer A., Robert M.E., Bifulco C.B., et al. Different cytokeratin and neuronal cell adhesion molecule staining patterns in focal nodular hyperplasia and hepatic adenoma and their significance. Hum Pathol 39 (2008) 1370-1377
93. Baumhoer D., Tzankov A., Dirnhofer S., et al. Patterns of liver infiltration in lymphoproliferative disease. Histopathology 53 (2008) 81-90
94. Krasinskas A.M., Ruchelli E.D., Rand E.B., et al. Central venulitis in pediatric liver allografts. Hepatology 33 (2001) 1141-1147
95. Demetris A.J. Central venulitis in liver allografts: considerations of differential diagnosis. Hepatology 33 (2001) 1329-1330
96. Hübscher S.G. Central perivenulitis: a common and potentially important finding in late posttransplant liver biopsies. Liver Transplant 14 (2008) 596-600
97. Abraham S.C., Freese D.K., Ishitani M.B., et al. Significance of central perivenulitis in pediatric liver transplantation. Am J Surg Pathol 32 (2008) 1479-1488
98. Krasinskas A.M., Demetris A.J., Poterucha J.J., et al. The prevalence and natural history of untreated isolated central perivenulitis in adult allograft livers. Liver Transplant 14 (2008) 625-632
99. Aberg F., Pukkala E., Höckerstedt K., et al. Risk of malignant neoplasms after liver transplantation: a population-based study. Liver Transplant 14 (2008) 1428-1436
100. Souza P., Prihoda T.J., Hoyumpa A.M., et al. Morphologic features resembling transplant rejection in core biopsies of native livers from patients with hepatitis C. Hum Pathol 40 (2009) 92-97
101. Misdraji J., Thiim M., and Graeme-Cook F.M. Autoimmune hepatitis with centrilobular necrosis. Am J Surg Pathol 28 (2004) 471-478
102. Zen Y., Notsumata K., Tanaka N., et al. Hepatic centrilobular zonal necrosis with positive antinuclear antibody: a unique subtype or early disease of autoimmune hepatitis?. Hum Pathol 38 (2007) 1669-1675
103. Te H.S., Koukoulis G., and Ganger D.R. Autoimmune hepatitis: a histological variant associated with prominent centrilobular necrosis. Gut 41 (1997) 269-271
104. Demetris A.J., and Sebagh M. Plasma cell hepatitis in liver allografts: variant of rejection or autoimmune hepatitis?. Liver Transplant 14 (2008) 750-755
105. Herzog D., Bouron-Dal Soglio D., Fournet J.-C., et al. Interface hepatitis is associated with a high incidence of late graft fibrosis in a group of tightly monitored pediatric orthotopic liver transplantation patients. Liver Transplant 14 (2008) 946-955
106. Fiel M.I., Agarwal K., Stanca C., et al. Posttransplant plasma cell hepatitis (de novo autoimmune hepatitis) is a variant of rejection and may lead to a negative outcome in patients with hepatitis C virus. Liver Transplant 14 (2008) 861-871
107. Khettry U., Huang W.-Y., Simpson M.A., et al. Patterns of recurrent hepatitis C after liver transplantation in a recent cohort of patients. Hum Pathol 38 (2007) 443-452
108. Berardi S., Lodato F., Gramenzi A., et al. High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis?. Gut 56 (2007) 237-242